| 1 |
34965304 | Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy. | 2022 Feb 8 |
1 |
| 2 |
33669329 | Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström's Macroglobulinemia. | 2021 Feb 16 |
1 |
| 3 |
33735664 | Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. | 2021 Apr |
1 |
| 4 |
34289017 | Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia. | 2021 Oct 28 |
1 |
| 5 |
32083995 | Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. | 2020 Apr 10 |
1 |
| 6 |
32580942 | In Human Visualization of Ibrutinib-Induced CLL Compartment Shift. | 2020 Aug |
1 |
| 7 |
32647793 | Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials. | 2020 Jun |
1 |
| 8 |
31267520 | CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib. | 2019 Nov |
5 |
| 9 |
31343930 | CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review. | 2019 Oct |
1 |
| 10 |
31570491 | CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia. | 2019 Oct 8 |
1 |
| 11 |
31695539 | Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia. | 2019 |
1 |
| 12 |
29280186 | Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound. | 2018 Aug |
1 |
| 13 |
29326436 | p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes. | 2018 Mar |
2 |
| 14 |
29869556 | A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia. | 2018 Sep |
1 |
| 15 |
30044692 | Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. | 2018 Sep 20 |
1 |
| 16 |
30190015 | Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond. | 2018 Oct |
1 |
| 17 |
28235842 | Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia. | 2017 May 4 |
1 |
| 18 |
28294689 | Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia. | 2017 Mar 20 |
3 |
| 19 |
28548645 | Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. | 2017 May 26 |
1 |
| 20 |
28641100 | Bruton's tyrosine kinase (BTK) as a promising target in solid tumors. | 2017 Jul |
1 |
| 21 |
28641630 | [SDF-1α/CXCR4 Mediated Drug Resistance Can be Reversed by Ibrutinib in Acute Lymphoblastic Leukemia]. | 2017 Jun |
7 |
| 22 |
29365396 | [Ibrutinib inhibits mesenchymal stem cells-mediated drug resistance in diffuse large B-cell lymphoma]. | 2017 Dec 14 |
6 |
| 23 |
27268124 | Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia. | 2016 Jul |
1 |
| 24 |
27287071 | Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status. | 2016 Dec 15 |
1 |
| 25 |
27480113 | Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. | 2016 Sep 22 |
1 |
| 26 |
31360080 | Waldenström macroglobulinemia: biology, genetics, and therapy. | 2016 |
1 |
| 27 |
24912431 | The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia. | 2015 Jan |
5 |
| 28 |
25371371 | CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells. | 2015 Mar |
8 |
| 29 |
25853747 | Ibrutinib in previously treated Waldenström's macroglobulinemia. | 2015 Apr 9 |
1 |
| 30 |
26138997 | Ibrutinib for the treatment of Waldenström macroglobulinemia. | 2015 Oct |
1 |
| 31 |
26282174 | Enhanced Chemokine Receptor Recycling and Impaired S1P1 Expression Promote Leukemic Cell Infiltration of Lymph Nodes in Chronic Lymphocytic Leukemia. | 2015 Oct 1 |
1 |
| 32 |
25294819 | Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML. | 2014 Oct 30 |
2 |